Find out what's behind their big run-ups to see if they can make it happen again.
News & Analysis: Marinus Pharmaceuticals
Investors are thrilled with the results from a late-stage clinical study of the company's only pipeline drug candidate.
The tech-heavy index is bouncing back from recent weakness.
Wall Street is not sold on the latest clinical results.
A secondary offering on the way isn't what investors wanted to hear.
The small biopharma announced second-quarter 2018 results and gave a business update.
The tiny biopharma is back on the upswing following an analyst upgrade.
The biopharma's slide continues -- for good reason this time.
The key to big gains last year? Start off small.
Learn why these stocks fell in a strong market.